

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application. Claims 1 and 7 are currently pending. Claims 2-6 and 8-18 are cancelled. Support for the amendment to claim 1 can be found in originally filed claims 6, 8 and 9. Support for the amendment to claim 7 can be found in originally filed claim 7 and in the Examples section of the disclosure.

Listing of Claims:

1. (Currently amended) A method for preventing or minimizing loss of bone mineral in mammals which method comprises administering to a mammal an amount of an aminoalkylenephosphonate or a pharmaceutically acceptable salt thereof which is effective to prevent or minimize loss of bone mineral density, wherein the aminoalkylenephosphonate is selected from the group consisting of 3,6,9,15-tetraazabicyclo[9.3.1]tetradeca-1(15),11,13-triene-3,6,9-trimethylenephosphonic acid (PCTMP), N,N'-bis(methylenephosphonic acid)-2,11-diaza[3.3](2,6)pyridinophane (BP2MP), and N,N-bis(methylenephosphonic acid)-2-(aminomethyl)pyridine (AMPDMP).
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Currently amended) The method according to Claim 1 A method for preventing or minimizing loss of bone mineral in mammals which method comprises administering to a mammal an amount of an aminoalkylenephosphonate or a pharmaceutically acceptable salt thereof which is effective to prevent or minimize loss of bone mineral density, wherein said aminoalkylenephosphonate is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP), with the proviso that the DOTMP is not complexed with Gallium III, Tin IV, Indium III, Samarium III or Cerium III.
8. (Cancelled)
9. (Cancelled)
10. (Cancelled).
11. (Cancelled).

Appln. No. 10/088,884
Response A dated January 16, 2004
Reply to Office Action of September 11, 2003

12. (Cancelled).
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).
16. (Cancelled).
17. (Cancelled).
18. (Cancelled).